Abstract
Background
The follow-up of patients treated for colorectal liver metastases (CRLM) is not standardized. The accuracy of an increase in carcinoembryonic antigen (CEA) levels for finding recurrences after treatment for CRLM is compared in this retrospective cohort study with the accuracy of routine imaging modalities of liver and chest.
Methods
Data from all patients in follow-up after intentionally curative treatment for CRLM from 1990 to 2010 were analyzed. All patients underwent the same follow-up schedule. The way in which recurrences became apparent (i.e., CEA increase, routine imaging, or both) was registered. The specificity and sensitivity of increases in CEA before finding recurrent disease were calculated by receiver operating characteristic (ROC) curves. An economic evaluation of the cost per resectable tumor recurrence was performed.
Results
ROC curves showed that a significant CEA increase was defined as a 25 % increase from the previous value. Recurrences were detected in 46 % of the procedures through CEA increase concomitant with positive imaging, in 23 % through CEA increase without positive findings on routine imaging, and in 31 % through positive imaging without an increase in CEA. The resectability of recurrences did not differ between triggers. Cost per curable recurrence was €2,196 for recurrences found via CEA alone and €6,721 for recurrences found with imaging and CEA.
Conclusions
In the follow-up of patients after liver surgery for CRLM, a 25 % increase in CEA serum level can accurately detect recurrences, but routine imaging is indispensable. In patients with CRLM, we advocate both CEA monitoring and imaging in the follow-up after liver surgery.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2007;1:CD002200.
de Jong KP. Multimodality treatment of liver metastases increases suitability for surgical treatment. Aliment Pharmacol Ther. 2007;26(Suppl 2):161–9.
Castells A, Bessa X, Daniels M, et al. Value of postoperative surveillance after radical surgery for colorectal cancer: results of a cohort study. Dis Colon Rectum. 1998;41:714–23.
Jatzko GR, Lisborg PH, Stettner HM, et al. Hepatic resection for metastases from colorectal carcinoma: a survival analysis. Eur J Cancer. 1995;31A:41–6.
Memon MA, Beckingham IJ. Surgical resection of colorectal liver metastases. Colorectal Dis. 2001;3:361–73.
House MG, Ito H, Gonen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210:744–52, 752–5.
Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982–99.
Bentrem DJ, Dematteo RP, Blumgart LH. Surgical therapy for metastatic disease to the liver. Annu Rev Med. 2005;56:139–56.
Goldberg RM, Fleming TR, Tangen CM, et al. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med. 1998;129:27–35.
Carpizo DR, D’Angelica M. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Lancet Oncol. 2009;10:801–9.
de Jong KP, Wertenbroek MWJLAE. Liver resection combined with local ablation: where are the limits? Dig Surg. 2011;28:125–31.
Bilchik AJ, Wood TF, Allegra D, et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg. 2000;135:657–62.
Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010;28:493–508.
Holm A, Bradley E, Aldrete JS. Hepatic resection of metastasis from colorectal carcinoma. Morbidity, mortality, and pattern of recurrence. Ann Surg. 1989;209:428–34.
Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–25.
de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250:440–8.
Metcalfe M, Mann C, Mullin E, et al. Detecting curable disease following hepatectomy for colorectal metastases. ANZ J Surg. 2005;75:524–7.
Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007;84:324–38.
Helmberger T. Interventional procedures for hepatic metastases. Chirurg. 2010;81:542–50.
Kobayashi H, Mochizuki H, Sugihara K, et al. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery. 2007;141(1):67–75.
Staab HJ, Anderer FA, Stumpf E, et al. Slope analysis of the postoperative CEA time course and its possible application as an aid in diagnosis of disease progression in gastrointestinal cancer. Am J Surg. 1978;136:322–7.
Niu R, Yan TD, Zhu JC, et al. Recurrence and survival outcomes after hepatic resection with or without cryotherapy for liver metastases from colorectal carcinoma. Ann Surg Oncol. 2007;14:2078–87.
Hohenberger P, Schlag PM, Gerneth T, et al. Pre- and postoperative carcinoembryonic antigen determinations in hepatic resection for colorectal metastases. Predictive value and implications for adjuvant treatment based on multivariate analysis. Ann Surg. 1994;219:135–43.
Oussoultzoglou E, Rosso E, Fuchshuber P, et al. Perioperative carcinoembryonic antigen measurements to predict curability after liver resection for colorectal metastases: a prospective study. Arch Surg. 2008;143:1150–8.
Bhattacharjya S, Aggarwal R, Davidson BR. Intensive follow-up after liver resection for colorectal liver metastases: results of combined serial tumour marker estimations and computed tomography of the chest and abdomen: a prospective study. Br J Cancer. 2006;95:21–6.
Staab HJ, Ahlemann LM, Anderer FA, et al. Optimizing tumor markers in breast cancer: monitoring, prognosis, and therapy control. Cancer Detect Prev. 1985;8:35–45.
Mann CD, Metcalfe MS, Neal CP, et al. Role of ultrasonography in the detection of resectable recurrence after hepatectomy for colorectal liver metastases. Br J Surg. 2007;94:1403–7.
Brenner DJ, Hall EH. Computed tomography: an increasing source of radiation exposure. N Engl J Med. 2007;357:2277–84.
Coakley FV, Gould R, Yeh BM, Arenson RL. CT radiation dose: what can you do right now in your practice? AJR Am J Roentgenol. 2011 Mar;196:619–25.
Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest X-ray, and colonoscopy. Ann Surg. 1998;228:59–63.
Acknowledgment
The authors thank professor Edwin van de Heuvel for his help with the ROC curve analysis.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Verberne, C.J., Wiggers, T., Vermeulen, K.M. et al. Detection of Recurrences During Follow-up After Liver Surgery for Colorectal Metastases: Both Carcinoembryonic Antigen (CEA) and Imaging are Important. Ann Surg Oncol 20, 457–463 (2013). https://doi.org/10.1245/s10434-012-2629-3
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-012-2629-3